Blueprint Medicines Corp

NASDAQ:BPMC   3:59:55 PM EDT
77.87
+1.98 (+2.61%)
Other Pre-Announcement

Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership

Published: 01/10/2022 13:22 GMT
Blueprint Medicines Corp (BPMC) - Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership.
Blueprint Medicines Corp - Achieved Full-year 2021 Preliminary Global Net Product Revenue for Ayvakit of Approximately $52.9 Million,.
Blueprint Medicines Corp - Plan to Report Initial Symphony Trial Data for Blu-945 in Egfr-driven Lung Cancer in 1h 2022.
Blueprint Medicines - FY 2021 Total Revenues, Including Collaboration Revenues, Expected to Be at Higher-end of Previous Guidance of $170-$180 Million.